Please assess the completion status of the following clinical trial:

Trial Title: Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must express HLA-A\*0201~* Patients who are currently undergoing or who previously underwent matched allogeneic HCT for:~  * AML: Prospective enrollment will now be limited to patients with relapsed disease (overt relapse or minimal residual disease) at any time post allogeneic HCT~ * MDS will no longer be a criterion for eligibility~ * CML will no longer be a criterion for eligibility~* Patients must have an HLA-matched donor of hematopoietic stem cells (related or unrelated)~* Patients must be able to provide blood and bone marrow samples and undergo the procedures required for this protocol~* Patients must be \>= 15 kg, as patients with lower weight would be incapable of providing high volume and frequent blood samples for monitoring and analysis~* Patients must be able to give informed consent; parent or legal representative will be asked to consent for patients younger than 18 year old~* DONOR: Patient and donor (related or unrelated) must be HLA-matched and express HLA-A\*0201~* DONOR: Donor must be Epstein-Barr virus (EBV) or cytomegalovirus (CMV) seropositive~* DONOR: Donor must be age 18 or older~* DONOR: In good general health~* DONOR: Able to give informed consent~Exclusion Criteria:~* Central nervous system (CNS) tumor refractory to intrathecal chemotherapy and/or cranio-spinal radiation~* In patients whose leukemic cells are available for evaluation, the expression of WT1 in the patient's bone marrow will be determined; if WT1 expression in the patient's bone marrow is not highly expressed by polymerase chain reaction (PCR), the patient will be excluded from the study; patients with no evaluable leukemia will be eligible for enrollment based on the high frequency of positive leukemias (\> 90%), and leukemia will be evaluated for WT1 expression if recurrence is detected~* Human immunodeficiency virus (HIV) seropositive; testing for HIV should be within 6 months of enrollment~* Medical or psychological conditions that would make the patient unsuitable candidate for cell therapy at the discretion of the principal investigator (PI)~* Pregnancy or breast-feeding; women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (B-hCG) pregnancy test result within 14 days before the first dose of WT1-specific T cell infusion; woman of non-childbearing potential will be defined as being postmenopausal greater than one year or who have had a bilateral tubal ligation or hysterectomy; all recipients of WT1-specific T cells will be counseled to use effective birth control during participation in this study and for 12 months after the last T cell infusion~* DONOR: Less than 18 years old~* DONOR: Active infectious hepatitis~* DONOR: HIV or human T-lymphotropic virus (HTLV) seropositive~* DONOR: Pregnancy or nursing~* DONOR: Significant medical conditions (e.g. immunosuppressive therapy) that would make the donor an unsuitable T cell donor~* DONOR: Unable to give informed consent

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (high-risk for relapse after HCT) (Type: EXPERIMENTAL): Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.
- Arm II (relapsed after HCT) (Type: EXPERIMENTAL): Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.

Based on this trial design, predict the completion outcome and termination type (if applicable).